Huntington disease: clinical consequences and therapeutic implications

[1]  N. Aziz,et al.  Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications , 2007, Reviews in the neurosciences.

[2]  R. Barker,et al.  Weight changes in Huntington's disease , 2006, European journal of neurology.

[3]  Å. Petersén,et al.  Hypothalamic–endocrine aspects in Huntington's disease , 2006, The European journal of neuroscience.

[4]  M. Hayden,et al.  Cerebrospinal fluid levels of orexin‐A are not a clinically useful biomarker for Huntington disease , 2006, Clinical genetics.

[5]  S. Tabrizi,et al.  Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. , 2006, Human molecular genetics.

[6]  H. Yoshimatsu,et al.  The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. , 2006, Trends in pharmacological sciences.

[7]  T. Stone,et al.  Blood 5‐hydroxytryptamine, 5‐hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury , 2006, Journal of neurochemistry.

[8]  M. Hayden,et al.  Body weight is modulated by levels of full-length huntingtin. , 2006, Human molecular genetics.

[9]  S. Lipton,et al.  Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior , 2006, Nature Medicine.

[10]  M. Hersberger,et al.  Hypocretin-1 (orexin A) levels are normal in Huntington’s disease , 2006, Journal of Neurology.

[11]  David Broadhurst,et al.  Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. , 2006, Brain : a journal of neurology.

[12]  A. Young,et al.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Kalsbeek,et al.  Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. , 2006, Endocrinology.

[14]  B. Wisse,et al.  Role of hypothalamic interleukin-1β (IL-1β) in regulation of energy homeostasis by melanocortins , 2006, Peptides.

[15]  H. Kotani,et al.  Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. , 2006, Journal of pharmacological sciences.

[16]  A. Kelley,et al.  Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward , 2005, Physiology & Behavior.

[17]  Blair R. Leavitt,et al.  Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease , 2005, Experimental Neurology.

[18]  E. Mignot,et al.  CSF hypocretin levels are normal in Huntington's disease patients. , 2005, Sleep.

[19]  B. Mollenhauer,et al.  Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease , 2005, Brain Research.

[20]  J. Olson,et al.  Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease , 2005, The Journal of Neuroscience.

[21]  D. Belsham,et al.  Anorexigenic Hormones Leptin, Insulin, and α-Melanocyte-Stimulating Hormone Directly Induce Neurotensin (NT) Gene Expression in Novel NT-Expressing Cell Models , 2005, The Journal of Neuroscience.

[22]  F. Sundler,et al.  Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease , 2005, The European journal of neuroscience.

[23]  A. Ochoa,et al.  Use of oral nutritional supplements in patients with Huntington's disease. , 2005, Nutrition.

[24]  L. Duntas,et al.  Leptin TRH and Ghrelin: Influence on Energy Homeostasis at Rest and During Exercise , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[25]  S. Dagogo-Jack,et al.  Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  C. Pagès,et al.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Hersch,et al.  Ethyl-EPA in Huntington disease , 2005, Neurology.

[29]  A. Morton,et al.  Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington’s disease is not improved by treatment with hypoglycaemic agents , 2005, Experimental Brain Research.

[30]  E. Fliers,et al.  Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. , 2005, The Journal of clinical endocrinology and metabolism.

[31]  Sarah J Tabrizi,et al.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker. , 2005, Human molecular genetics.

[32]  Karen Marder,et al.  Energy balance in early-stage Huntington disease. , 2005, The American journal of clinical nutrition.

[33]  B. Landwehrmeyer,et al.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[34]  Andon Hestiantoro,et al.  Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. , 2005, Brain : a journal of neurology.

[35]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[36]  N. Nukina,et al.  Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine‐EGFP fluorescent aggregates , 2005, Journal of neurochemistry.

[37]  H. Pijl,et al.  Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. , 2005, American journal of physiology. Endocrinology and metabolism.

[38]  D. Swaab,et al.  Increased melanin concentrating hormone receptor type I in the human hypothalamic infundibular nucleus in cachexia. , 2005, The Journal of clinical endocrinology and metabolism.

[39]  M. Panas,et al.  Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.

[40]  S. Lewis,et al.  The use of the Actiwatch–Neurologica® system to objectively assess the involuntary movements and sleep–wake activity in patients with mild–moderate Huntington’s disease , 2005, Journal of Neurology.

[41]  Erik Renström,et al.  The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. , 2005, Human molecular genetics.

[42]  R. Athanazio,et al.  Central H1 and H2 receptor participation in the control of water and salt intake in rats , 2005, Physiology & Behavior.

[43]  R. Barker,et al.  Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease , 2005, The Journal of Neuroscience.

[44]  H. Tanila,et al.  Orexin loss in Huntington's disease. , 2005, Human molecular genetics.

[45]  N. Nukina,et al.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules , 2005, Journal of Molecular Medicine.

[46]  J. Siegel,et al.  The neurotransmitters of sleep. , 2004, The Journal of clinical psychiatry.

[47]  B. Peterlin,et al.  Early sympathetic hyperactivity in Huntington's disease , 2004, European journal of neurology.

[48]  M. Cowley,et al.  The electrophysiology of feeding circuits , 2004, Trends in Endocrinology & Metabolism.

[49]  Thomas H Gillingwater,et al.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation , 2004, The European journal of neuroscience.

[50]  P. Joseph-Bravo.  Hypophysiotropic thyrotropin-releasing hormone neurons as transducers of energy homeostasis. , 2004, Endocrinology.

[51]  U. Das,et al.  Essential fatty acids in Huntington's disease. , 2004, Nutrition.

[52]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[53]  Jane S. Paulsen,et al.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.

[54]  Jean-François Gagnon,et al.  Sleep and quantitative EEG in neurodegenerative disorders. , 2004, Journal of psychosomatic research.

[55]  E. Eşel,et al.  Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  M. Beal,et al.  The Energetics of Huntington's Disease , 2004, Neurochemical Research.

[57]  G. Sobue,et al.  Sweet relief for Huntington disease , 2004, Nature Medicine.

[58]  J. Corey-Bloom,et al.  Rate and correlates of weight change in Huntington’s disease* , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  A. Ochoa,et al.  Assessment of the nutrition status of patients with Huntington's disease. , 2004, Nutrition.

[60]  J Kassubek,et al.  Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[61]  N. Nukina,et al.  Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease , 2004, Nature Medicine.

[62]  P. Goldman-Rakic,et al.  Evidence for progression in frontal cortical pathology in late‐stage Huntington's disease , 2004, The Journal of comparative neurology.

[63]  M. Dose,et al.  Nocturnal sleep in huntington's disease , 1991, Journal of Neurology.

[64]  G. Beverstock.  The current state of research with peripheral tissues in Huntington disease , 2004, Human Genetics.

[65]  D. Swaab.  The human hypothalamus: basic and clinical aspects. Part II: neuropathy of the human hypothalamus and adjacent brain structures [handbook of clinical neurology; 3rd series vol. 2][series eds.: Aminoff, M.J., Boller F., Swaab, D. F.] , 2004 .

[66]  H. Oepen,et al.  Aminosäuren des Blutes bei Huntingtonscher Chorea , 2004, Humangenetik.

[67]  K. Schimrigk,et al.  Changes in nocturnal sleep in Huntington's and Parkinson's disease , 2004, Journal of Neurology.

[68]  H. Oepen,et al.  Statistische Befunde zur Klinik der Huntingtonschen Chorea , 2004, Archiv für Psychiatrie und Nervenkrankheiten.

[69]  G. W. Bruyn,et al.  Neuropathological changes of the nucleus accumbens in Huntington's chorea , 2004, Acta Neuropathologica.

[70]  E. Mignot,et al.  Relationship between CSF hypocretin levels and hypocretin neuronal loss , 2003, Experimental Neurology.

[71]  A. Kalsbeek,et al.  Central nervous determination of food storage--a daily switch from conservation to expenditure: implications for the metabolic syndrome. , 2003, European journal of pharmacology.

[72]  A. Kalsbeek,et al.  White Adipose Tissue: Getting Nervous , 2003, Journal of neuroendocrinology.

[73]  A. Kalsbeek,et al.  Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. , 2003, Diabetes.

[74]  Zhao-Xue Yu,et al.  Lack of Huntingtin-Associated Protein-1 Causes Neuronal Death Resembling Hypothalamic Degeneration in Huntington's Disease , 2003, The Journal of Neuroscience.

[75]  B. Wisse,et al.  Melanocortin Signaling and Anorexia in Chronic Disease States , 2003, Annals of the New York Academy of Sciences.

[76]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[77]  M. Thorén,et al.  Growth hormone treatment improves body composition in adults with Prader–Willi syndrome , 2003, Clinical endocrinology.

[78]  O. Wolkowitz,et al.  DHEA treatment of Alzheimer’s disease , 2003, Neurology.

[79]  H. Pijl,et al.  Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. , 2003, American journal of physiology. Endocrinology and metabolism.

[80]  M. Mattson,et al.  Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  D. Swaab.  The Human Hypothalamus. Basic and Clinical Aspects : part I: Nuclei of the human hypothalamus. , 2003 .

[82]  Ole A. Andreassen,et al.  Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression , 2002, Neurobiology of Disease.

[83]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[84]  S. Petersenn.  Growth Hormone Secretagogues and Ghrelin: An Update on Physiology and Clinical Relevance , 2002, Hormone Research in Paediatrics.

[85]  H. Pijl,et al.  Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. , 2002, The Journal of clinical endocrinology and metabolism.

[86]  H. Przuntek,et al.  Autonomic nervous system function in Huntington's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[87]  H. Pijl,et al.  Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. , 2002, The Journal of clinical endocrinology and metabolism.

[88]  E. Chiu,et al.  A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids , 2002, Neuroreport.

[89]  J. Hajnal,et al.  MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment , 2002, Neuroreport.

[90]  J. Drago,et al.  Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease , 2002, Neuroscience.

[91]  J. Schiefer,et al.  Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.

[92]  O. Andreassen,et al.  Lipoic acid improves survival in transgenic mouse models of Huntington's disease , 2001, Neuroreport.

[93]  B. Puri.  Impaired Phospholipid‐Related Signal Transduction in Advanced Huntington's Disease , 2001, Experimental physiology.

[94]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[95]  Jon T. Willie,et al.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness. , 2001, Annual review of neuroscience.

[96]  T. Foroud,et al.  Progression of symptoms in the early and middle stages of Huntington disease. , 2001, Archives of neurology.

[97]  A. Reiner,et al.  Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. , 2001, Human molecular genetics.

[98]  E. Richelson,et al.  Neurotensin: peptide for the next millennium , 2000, Regulatory Peptides.

[99]  D. Manners,et al.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.

[100]  Eileen M. McKay,et al.  Weight loss in Huntington's disease , 2000, Annals of neurology.

[101]  W. Maragos,et al.  Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.

[102]  O. Andreassen,et al.  Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice , 2000, Journal of neurochemistry.

[103]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[104]  E. Ravussin,et al.  Higher sedentary energy expenditure in patients with Huntington's disease , 2000, Annals of neurology.

[105]  E. Nillni,et al.  The biology of pro-thyrotropin-releasing hormone-derived peptides. , 1999, Endocrine reviews.

[106]  J. Romano,et al.  Sympathetic skin response and heart rate variability in patients with Huntington disease. , 1999, Archives of neurology.

[107]  Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  M. Hurlbert,et al.  Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. , 1999, Diabetes.

[109]  E. Perry,et al.  Distribution of histamine H3‐receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases , 1999, The European journal of neuroscience.

[110]  P S Kalra,et al.  Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. , 1999, Endocrine reviews.

[111]  I. Karydis,et al.  Orexis, anorexia, and thyrotropin-releasing hormone. , 1998, Thyroid : official journal of the American Thyroid Association.

[112]  S. Carr,et al.  Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior , 1998, Cell.

[113]  F. Leblhuber,et al.  Activated Immune System in Patients with Huntington's Disease , 1998, Clinical chemistry and laboratory medicine.

[114]  N. Taylor,et al.  Sleep disturbance and Huntingdon's disease , 1997, British Journal of Psychiatry.

[115]  M. Beal,et al.  Cortical peptide changes in Huntington's disease may be independent of striatal degeneration , 1997, Annals of neurology.

[116]  G. Gillies.  Somatostatin: the neuroendocrine story. , 1997, Trends in pharmacological sciences.

[117]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[118]  N. Ling,et al.  Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  S. Chokroverty.  Sleep and degenerative neurologic disorders. , 1996, Neurologic clinics.

[120]  M. Nance,et al.  Characteristics of individuals with Huntington disease in long‐term care , 1996, Movement disorders : official journal of the Movement Disorder Society.

[121]  D. Swaab,et al.  Somatostatin 1–12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients , 1996, Brain Research.

[122]  C. Ross,et al.  Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.

[123]  A. Tisano,et al.  Sleep features in Tourette's syndrome, neuroacanthocytosis and Huntington's chorea , 1995, Neurophysiologie Clinique/Clinical Neurophysiology.

[124]  F. Leblhuber,et al.  Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea , 1995, Journal of the Neurological Sciences.

[125]  D F Swaab,et al.  Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. , 1995, The American journal of psychiatry.

[126]  R. Reilmann,et al.  Decreased plasma alanine and isoleucine in Huntington's disease , 1995, Acta neurologica Scandinavica.

[127]  J. Veldhuis,et al.  Analytical methods for evaluating episodic secretory activity within neuroendocrine axes , 1994, Neuroscience & Biobehavioral Reviews.

[128]  D. Swaab,et al.  Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. , 1994, Neuroendocrinology.

[129]  Stable vasopressin innervation in the degenerating human locus coeruleus in Alzheimer's disease , 1994, Brain Research.

[130]  S. Folstein,et al.  Sexual disorders in Huntington's disease. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[131]  J. Schwartz,et al.  Loss of striatal histamine H2 receptors in Huntington's: Chorea but not in Parkinson's disease: Comparison with animal models , 1993, Synapse.

[132]  M. Pascoe.  Huntington's disease and low tryptophan diet. , 1993, Medical hypotheses.

[133]  H. Kremer,et al.  Demise of a neuronal population in huntington's disease and the importance of hyponeuronogenesis , 1992, Clinical Neurology and Neurosurgery.

[134]  M. C. Kagel,et al.  Dysphagi in Huntington's disease: A 16-year retrospective , 1992, Dysphagia.

[135]  R. Roos,et al.  Weight loss in Huntington's disease. , 1992, Archives of neurology.

[136]  I. Heuser,et al.  The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease , 1991, Biological Psychiatry.

[137]  H. Kremer,et al.  The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease , 1991, Neuroscience Letters.

[138]  M. Konagaya,et al.  [Abnormality of hypothalamic dopaminergic system in neuro-degenerative diseases--evaluation of alpha-melanocyte-stimulating hormone-like immunoreactivity in cerebrospinal fluid]. , 1991, Rinsho shinkeigaku = Clinical neurology.

[139]  D. Sax,et al.  Factors associated with slow progression in Huntington's disease. , 1991, Archives of neurology.

[140]  J. Unger,et al.  Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord , 1991, Journal of Chemical Neuroanatomy.

[141]  I. Goto,et al.  Chorea‐acanthocytosis: Abnormal composition of covalently bound fatty acids of erythrocyte membrane proteins , 1991, Annals of neurology.

[142]  C. Marsden,et al.  The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. , 1991, Archives of neurology.

[143]  E Maran,et al.  Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.

[144]  L. M. Morales,et al.  Nutritional evaluation of Huntington disease patients. , 1989, The American journal of clinical nutrition.

[145]  H. Kremer,et al.  Endocrine functions in Huntington's disease A two-and-a-half years follow-up study , 1989, Journal of the Neurological Sciences.

[146]  J. Coyle,et al.  Cerebrospinal fluid correlates of depression in Huntington's disease. , 1988, Archives of neurology.

[147]  M. Lanska,et al.  Conditions associated with Huntington's disease at death. A case-control study. , 1988, Archives of neurology.

[148]  Joseph B. Martin,et al.  Somatostatin and neuropeptide Y concentrations in pathologically graded cases of huntington's disease , 1988, Annals of neurology.

[149]  D. Lanska,et al.  Huntington's disease mortality in the United States , 1988, Neurology.

[150]  J. G. van Dijk,et al.  Autonomic nervous function in Huntington's disease. , 1988, Archives of neurology.

[151]  C. Tamminga,et al.  The endocrinology of extrapyramidal system disorders. , 1988, Endocrinology and metabolism clinics of North America.

[152]  S. Folstein,et al.  Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease , 1987, Brain Research.

[153]  D. Kromhout,et al.  Which factors influence age at onset and rate of progression in Huntington's disease? , 1987, Journal of the Neurological Sciences.

[154]  Joseph B. Martin,et al.  Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease , 1987, Brain Research.

[155]  L. Carenini,et al.  Parasympathetic function in Huntington's disease. , 1987, Functional neurology.

[156]  C. Kannan.  Thyrotropin and Thyrotropin-Releasing Hormone , 1987 .

[157]  Joseph B. Martin,et al.  Neuropeptides in neurological disease , 1986, Annals of neurology.

[158]  P. Emson,et al.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease , 1985, Brain Research.

[159]  L. Farrer,et al.  An anthropometric assessment of Huntington's disease patients and families. , 1985, American journal of physical anthropology.

[160]  L. Farrer,et al.  Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. , 1985, American journal of medical genetics.

[161]  L. Farrer.  Diabetes mellitus in Huntington disease , 1985, Clinical genetics.

[162]  Iakhno Nn.  Disorders of nocturnal sleep in Huntington chorea , 1985 .

[163]  M. C. Kagel,et al.  Dysphagia in Huntington's disease. , 1985, Archives of neurology.

[164]  R. Roos,et al.  Neuronal nuclear membrane indentation and astrocyte/neuron ratio in Huntington's disease. A quantitative electron microscopic study. , 1985, Journal fur Hirnforschung.

[165]  W. Maltese.  Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease. , 1984, Biochemical medicine.

[166]  F. Schroeder,et al.  Membrane Anomalies in Huntington's Disease Fibroblasts , 1984, Journal of neurochemistry.

[167]  Joseph B. Martin,et al.  Somatostatin is increased in the nucleus accumbens in Huntington's disease , 1984, Neurology.

[168]  C. Tamminga,et al.  Neuroendocrine Studies in Huntington’s Disease , 1984 .

[169]  C. Tamminga,et al.  Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[170]  J. Lakowicz,et al.  Evidence for normal fibroblast cell membranes from individuals with Huntington's disease A fluorescence probe study , 1983, Journal of the Neurological Sciences.

[171]  S. Folstein,et al.  The nucleus basalis in Huntington's disease , 1983, Neurology.

[172]  C. Nemeroff,et al.  Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. , 1983, Science.

[173]  C. Tamminga,et al.  Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease , 1983, Neurology.

[174]  Joseph B. Martin,et al.  Somatostatin is increased in the basal ganglia in Huntington disease , 1983, Annals of neurology.

[175]  S. Hunt,et al.  Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease , 1982, Brain Research.

[176]  J. Lakowicz,et al.  Fluorescence Studies of Red Blood Cell Membranes from Individuals with Huntington's Disease , 1982, Journal of neurochemistry.

[177]  G. Beverstock,et al.  Membrane fluidity measurements in peripheral cells from Huntington's disease patients , 1981, Journal of neurology, neurosurgery, and psychiatry.

[178]  I. Bone,et al.  Studies of hypothalamic function in Huntington's chorea. , 1981, Journal of neurology, neurosurgery, and psychiatry.

[179]  H. Fibiger,et al.  BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.

[180]  J. Lakowicz,et al.  Fluorescence spectroscopic studies of Huntington fibroblast membranes. , 1981, American journal of human genetics.

[181]  A. Destée,et al.  [Huntington's chorea and somatotropic hormone: dynamic explorations in 27 cases (author's transl)]. , 1981, Revue neurologique.

[182]  L. Murri,et al.  Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. , 1980, European neurology.

[183]  W. Tourtellotte,et al.  Growth hormone and prolactin secretion in Huntington's disease. , 1979, Life sciences.

[184]  S. Fahn,et al.  Huntington disease , 1979, Neurology.

[185]  J. Panksepp,et al.  Anatomy of the hypothalamus , 1979 .

[186]  T. Chase,et al.  Stimulation of Prolactin and Growth Hormone Secretion by Muscimol, a γ-Aminobutyric Acid Agonist , 1978 .

[187]  E. Caine,et al.  Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release. , 1978, Life sciences.

[188]  R. Chalmers,et al.  Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[189]  P. Mantegazza,et al.  PROLACTIN CONTROL IN HUNTINGTON'S CHOREA , 1977, The Lancet.

[190]  M. Hayden,et al.  IMPAIRED PROLACTIN RELEASE IN HUNTINGTON'S CHOREA EVIDENCE FOR DOPAMINERGIC EXCESS , 1977, The Lancet.

[191]  D. Cocchi,et al.  Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. , 1977, The Journal of clinical endocrinology and metabolism.

[192]  J. Menkes,et al.  Huntington's disease—growth of fibroblast cultures in lipid‐deficient medium: A preliminary report , 1977, Annals of neurology.

[193]  O. Phillipson,et al.  Plasma glucose, non-esterified fatty acids and amino acids in Huntington's chorea. , 1977, Clinical science and molecular medicine.

[194]  J. V. Van Buren,et al.  Cerebrospinal fluid norepinephrine reductions in man after degeneration and electrical stimulation of the caudate nucleus , 1977, Annals of neurology.

[195]  S. Podolsky,et al.  Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. , 1977, Gerontology.

[196]  H. Kaffarnik,et al.  [Fatty acid patterns and glucose tolerance in Huntington's chorea (author's transl)]. , 1976, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[197]  O. Phillipson,et al.  Plasma growth hormone concentrations in Huntington's chorea. , 1976, Clinical science and molecular medicine.

[198]  G. Fink,et al.  Brain immunoreactive gonadotropin-releasing hormone in Huntington's chorea and in non-choreic subjects , 1976, Nature.

[199]  W. R. Sulaiman,et al.  Altered growth hormone release in Huntington's chorea. , 1976, Journal of neurology, neurosurgery, and psychiatry.

[200]  S. Podolsky,et al.  Exaggerated growth hormone response to arginine infusion in Huntington's disease. , 1975, The Journal of clinical endocrinology and metabolism.

[201]  M. Davidson,et al.  Normal glucose, insulin, and growth hormone responses to oral glucose in Huntington's disease , 1974 .

[202]  S. Podolsky,et al.  Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration. , 1974, The Journal of clinical endocrinology and metabolism.

[203]  M. Aminoff,et al.  Vasoregulatory activity in patients with Huntington's chorea. , 1974, Journal of the neurological sciences.

[204]  M. Aminoff,et al.  A study of vasomotor function in patients with Huntington's chorea. , 1973, Clinical science and molecular medicine.

[205]  C. Yates,et al.  Lysosomal enzymes, amino acids and acid metabolites of amines in Huntington's chorea. , 1973, Clinica chimica acta; international journal of clinical chemistry.

[206]  Shirley Hansen,et al.  Huntington's Chorea , 1973 .

[207]  D. Sax,et al.  Increased frequency of diabetes mellitus in patients with Huntington's chorea. , 1972, Lancet.

[208]  G. Bruyn,et al.  Huntington's chorea and the adrenal. , 1972, British medical journal.

[209]  J. Ottosson,et al.  SERUM LEVELS OF PHENYLALANINE AND TYROSINE IN HUNTINGTON'S CHOREA , 1971, Acta psychiatrica Scandinavica. Supplementum.

[210]  J. Wherrett,et al.  Erythrocyte glycolipids in Huntington's chorea , 1969, Neurology.

[211]  T. Perry,et al.  Plasma-aminoacid levels in Huntington's chorea. , 1969, Lancet.

[212]  G. W. Bruyn,et al.  Biochemical studies in Huntington's chorea , 1966, Neurology.

[213]  Bruyn Gw.  Biochemical studies in Huntington's chorea. 3. Aminoacids in serum and urine. , 1966 .

[214]  G. Bruyn,et al.  Biochemical studies in Huntington's chorea. 4. The fatty acid composition of plasma and erythrocyte lipids. , 1966, Psychiatria, neurologia, neurochirurgia.

[215]  W. Wahren.  Zur Pathoklise des Nucleus Tuberis Lateralis , 1964 .

[216]  H. Oepen.  [On 217 body dissection findings in Huntington's disease]. , 1963, Beitrage zur pathologischen Anatomie und zur allgemeinen Pathologie.

[217]  V. Cowie,et al.  Urinary alanine excretor in a Huntington's chorea family. , 1962, The Journal of mental science.

[218]  Reed Te,et al.  Huntington's chorea in Michigan. 2. Selection and mutation. , 1959 .

[219]  O. Vogt,et al.  Precipitating and modifying agents in chorea. , 1952, The Journal of nervous and mental disease.

[220]  M. Schöpe.  Über Veränderungen im pyramidal-motorischen System bei einer Chorea Huntington , 1940 .